Drugmakers Pfizer and BioNTech have announced that their two-dose COVID-19 vaccine is safe and shows a robust antibody response in children ages five to 11.
The vaccine makers conducted a study in which about 2,270 children in that age group were administered one-third of the adult dose, or 10 micrograms given three weeks apart.
The companies said the shots were well tolerated and produced an immune response and side effects comparable to those seen in a study of people ages 16 to 25.
However, there are not yet enough cases on which to report efficacy.
The companies plan to submit its findings to the US Food and Drug Administration for emergency use authorization soon.
Readers Bureau, Contributor
Edited by Jesus Chan
Do you want to add feedback to this story?
Please add a comment in the box below or send an email to firstname.lastname@example.org, send us a message on WhatsApp at 646-874-7976 or Call us at 201-500-7715